HYPERINSULINISM IN INFANTS AND CHILDREN
Section snippets
β-CELL REGULATION OF INSULIN SECRETION
Figure 1 briefly outlines the pathways involved in regulation of insulin secretion by the pancreatic β cell19 and indicates the site of action of diazoxide and somatostatin, drugs that may be useful in treatment of patients with hyperinsulinism. Glucose and other fuels, such as amino acids, stimulate insulin secretion through their metabolism to raise the intracellular ratio of ATP to ADP. Glucokinase, the enzyme that initiates β-cell glucose metabolism, has a high Km for glucose and, thus, the
Infants of Diabetic Mothers
Hyperinsulinism in infants of diabetic mothers is a well-recognized and well-understood disorder. Poorly controlled maternal diabetes exposes the fetus to excessively high levels of glucose, which results in fetal hyperinsulinism and excessive fetal growth. These infants are typically large for gestational age (LGA) and are at high risk for hypoglycemia immediately after birth. High rates of glucose administration are required until β-cell insulin regulation adapts to normoglycemia, which
CLINICAL MANIFESTATIONS OF HYPERINSULINISM
The primary feature of hyperinsulinism is recurrent episodes of symptomatic hypoglycemia. In severe cases, such as neonatal onset congenital hyperinsulinism, hypoglycemia occurs soon after or even despite feedings. In patients with milder cases, symptomatic hypoglycemia may not develop until the patient has fasted for 12 to 24 hours, although blood sugar levels tend to be erratic and fasting tolerance unpredictable. Signs and symptoms in neonates and young infants usually include seizures.
DIAGNOSIS OF HYPERINSULINISM
Hyperinsulinism can be suspected based on clinical clues, such as LGA (or SGA) birthweight, perinatal asphyxia, or high glucose requirement. The diagnosis can only be established by analysis of circulating hormone and substrate concentrations at times of hypoglycemia,26 however. Blood specimens taken during hypoglycemia have been termed the critical blood sample not only because they are obtained when the patient is, or is on the brink of becoming, critically ill but also because the laboratory
TREATMENT OF HYPERINSULINISM
Figure 3 diagrams a logical sequence of medical and surgical steps to control hypoglycemia in patients with hyperinsulinism.24, 28 Treatment must be aggressively applied to prevent the possibility of severe and irreversible brain damage. The goals for therapy are to achieve a regimen that is practical for use at home and that successfully keeps the blood glucose levels at more than 60 mg/dL while the child is on a feeding schedule that is age appropriate.3 Ideally, successful treatment implies
PROGNOSIS
In the past, it was speculated that there is a spontaneous remission of congenital hyperinsulinism or that the disorder may progress to diabetes mellitus.24 This has sometimes had the unfortunate consequence of fostering a gradualistic approach to therapy and a high risk for brain damage caused by inadequate control of hypoglycemia. Based on the increasing evidence that genetic defects of β-cell regulation are responsible for most cases, it now seems likely that remission of congenital
FUTURE DIRECTIONS
The increasing evidence that most cases of congenital hyperinsulinism have a genetic basis has important implications. Families with affected children should be provided genetic counseling and information about a possible 25% risk for recurrence. Information about specific genetic defects is clearly necessary for improving the treatment of this group of disorders. Only one genetic disorder, recessively inherited SUR defects, has been clearly defined, but others are likely to be recognized in
References (34)
- et al.
Management of hyperinsulinism in infants [editorial]
J Pediatr
(1991) - et al.
Hyperinsulinism in asphyxiated and small-for-dates infants with hypoglycaemia
Lancet
(1984) - et al.
Glycemic response to glucagon during fasting hypoglycemia: An aid in the diagnosis of hyperinsulinism
J Pediatr
(1980) - et al.
Pancreatic adenomas in infants and children: Current surgical management
J Pediatr Surg
(1978) - et al.
Persistent hyperinsulinemic hypoglycemia of infancy: Long-term octreotide treatment without pancreatectomy
J Pediatr
(1993) - et al.
Hyperinsulinism in infants and children: Diagnosis and therapy
Adv Pediatr
(1976) - et al.
Familial and sporadic hyperinsulinism: Histopathologic findings and segregation analysis support a single autosomal recessive disorder
J Pediatr
(1991) - et al.
Biochemical evaluation of a patient with a familial form of leucine-sensitive hypoglycemia and concomitant hyperammonemia
Metabolism
(1996) - et al.
Cloning of the β cell high-affinity sulfonylurea receptor: A regulator of insulin secretion
Science
(1995) - et al.
Nesidioblastosis of the pancreas: Definition of the syndrome and the management of the severe neonatal hypoglycemia
Arch Dis Child
(1981)
Familial hypoglycemia precipitated by amino acids
J Clin Invest
Hyperinsulinaemic hypoglycaemia in small for dates babies
Arch Dis Child
Leucine induced hypoglycemia: A review and speculations
Am J Med Sci
Long-term treatment with the somatostatin analogue SMS 201-995: Alternative to pancreatectomy in persistent hyperinsulinaemic hypoglycaemia of infancy
Digestion
Familial hyperinsulinism maps to chromosome 11p14-15.1 30 cM centromeric to the insulin gene
Nat Genet
Recombinant mapping of the familial hyperinsulinism gene to an 0.8 cm region on chromosome 11p15.1 and demonstration of a founder effect in Ashkenazi Jews
Hum Mol Genet
Combined defect of long-chain 3-hydroxyacyl-CoA dehydrogenase, 2-enoyl-CoA hydratase and 3-oxoacyl-CoA thiolase
Prog Clin Biol Res
Cited by (199)
Neonatal Hypoglycemia
2023, Principles of NeonatologyProduction and purification of ATP-sensitive potassium channel particles for cryo-electron microscopy
2021, Methods in EnzymologyLaparoscopic resection of pancreatic neck lesion with Roux-en-Y pancreatico-jejunostomy
2019, Journal of Pediatric Surgery Case ReportsNatural history and neurodevelopmental outcomes in perinatal stress induced hyperinsulinism
2022, Frontiers in Pediatrics
Address reprint requests to Charles A. Stanley, MD, Division of Endocrinology, The Children's Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104
Supported in part by grants from the National Institutes of Health, RR-00240 and RO1-DK43841.
- *
From the Division of Endocrinology, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania